ArticleNPJ breast cancer2025

Spatial biomarkers of response to eribulin plus pembrolizumab in patients with metastatic triple negative breast cancer in the ENHANCE-1 trial.

Yee Hoon Foong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.